Thiogenesis Therapeutics Past Earnings Performance
Past criteria checks 0/6
Thiogenesis Therapeutics's earnings have been declining at an average annual rate of -37.2%, while the Biotechs industry saw earnings growing at 13.8% annually.
Key information
-37.2%
Earnings growth rate
4.7%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -91.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Thiogenesis Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -5 | 1 | 4 |
| 30 Sep 23 | 0 | -3 | 1 | 2 |
| 30 Jun 23 | 0 | -3 | 1 | 2 |
| 31 Mar 23 | 0 | -3 | 1 | 2 |
| 31 Dec 22 | 0 | -4 | 1 | 1 |
| 30 Sep 22 | 0 | -4 | 1 | 1 |
| 30 Jun 22 | 0 | -3 | 1 | 1 |
| 31 Mar 22 | 0 | -3 | 0 | 1 |
| 31 Dec 21 | 0 | -1 | 0 | 1 |
Quality Earnings: TTI is currently unprofitable.
Growing Profit Margin: TTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TTI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: TTI has a negative Return on Equity (-91.55%), as it is currently unprofitable.